Integrated BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
February 10, 2023 at 04:32 pm
Share
Integrated BioPharma, Inc. reported earnings results for the second quarter and six months ended December 31, 2022. For the second quarter, the company reported sales was USD 12.25 million compared to USD 14.59 million a year ago. Net loss was USD 0.055 million compared to net income of USD 1.03 million a year ago.
For the six months, sales was USD 24.58 million compared to USD 27.35 million a year ago. Net loss was USD 0.09 million compared to net income of USD 1.55 million a year ago.
Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Companyâs business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.
INTEGRATED BIOPHARMA, INC. 
